L-Glutamine 관련 Crohn's Disease
CSmall RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.
Key Study Findings
Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None
vs: None
Outcome: Gut microbiota composition
효과: None
None
대상 집단: Crohn's disease patients
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
효과: None
None
대상 집단: Mouse model
Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT)
vs: Pre-treatment baseline
Outcome: Clinical remission and multi-omics changes
효과: None
None
대상 집단: Patients with Crohn's disease
In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic)
vs: Wild-type mice
Outcome: Cytokine production in macrophage activation
효과: None
None
대상 집단: Beclin1 variant mice + AIEC infection
Observational Study
n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured)
vs: Healthy controls (n=126)
Outcome: PAGln association with CD and colitis
효과: None
None
대상 집단: New-onset treatment-naive CD (n=136) + controls
Observational Study
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Dose: None
vs: None
Outcome: CAM use patterns in IBD patients
효과: None
None
대상 집단: Brazilian IBD patients
Key Statistics
3
연구
200
참여자
↑
Positive
C
등급
Referenced Papers
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Other
EMBO molecular medicine
2024
13 인용
Cannabis and cannabinoid …
2024
10 인용
World journal of …
2024
Cell reports
2023
27 인용
Journal of Crohn's …
2023
24 인용
JCI insight
2022
24 인용
Sheng wu gong …
2022
4 인용
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Other
Arquivos de gastroenterologia
2022
4 인용
Effects of glutamine supplementation on inflammatory bowel disease: A systematic review of clinical trials.
Systematic Review
Clinical nutrition ESPEN
2021
39 인용
Gastroenterology
2019
118 인용
Journal of cellular …
2019
23 인용
The Cochrane database …
2018
425 인용
Gastroenterology clinics of …
2018
67 인용
Clinical medicine insights. …
2018
15 인용
Nutrition in clinical …
2018
10 인용
Current opinion in …
2017
37 인용
JPEN. Journal of …
2017
24 인용
World journal of …
2017
21 인용
The AAPS journal
2017
Glutamine for induction of remission in Crohn's disease.
Systematic Review
The Cochrane database …
2016
37 인용
Scandinavian journal of …
2014
56 인용
Digestive diseases and …
2012
81 인용
Frontline gastroenterology
2012
20 인용
Plasma citrulline concentration as a marker for disease activity in patients with Crohn's disease.
Other
Journal of clinical …
2012
13 인용
Pediatrics in review
2012
International journal of …
2011
12 인용
Inflammatory bowel diseases
2010
89 인용
Nutricion hospitalaria
2010
Nutrition in clinical …
2009
36 인용
The Journal of …
2008
89 인용
Molecular nutrition & …
2008
26 인용
The Cochrane database …
2007
192 인용
Digestive diseases and …
2006
73 인용
Immunonutrition.
Review
Current opinion in …
2005
22 인용
JPEN. Journal of …
2005
19 인용
Clinical nutrition (Edinburgh, …
2004
18 인용
Medycyna wieku rozwojowego
2004
1 인용
Annali italiani di …
2004
Alimentary pharmacology & …
2003
179 인용
Nutricion hospitalaria
2003
Revista do Hospital …
2002
39 인용
Scandinavian journal of …
2002
28 인용
Enteral feeding.
Other
Current opinion in …
2002
1 인용
Enteral feeding.
Review
Current opinion in …
2002
Enteral nutritional therapy for inducing remission of Crohn's disease.
Systematic Review
The Cochrane database …
2001
149 인용
Journal of pediatric …
2000
187 인용
Current opinion in …
2000
21 인용
JPEN. Journal of …
2000
18 인용
JPEN. Journal of …
1999
129 인용
Diseases of the …
1998
26 인용
Zeitschrift fur Gastroenterologie
1998
18 인용
FASEB journal : …
1997
170 인용
Schweizerische medizinische Wochenschrift. …
1996
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
상한량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Washed microbiota transplantation (WMT) | -- | Positive | -- |
| Beclin1 constitutive activation (genetic) | -- | Positive | -- |
| Phenylacetylglutamine (PAGln, measured) | -- | Negative | 262 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Mixed | -- |
권장 복용 시간: Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
알려진 상호작용
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
일일 최대 섭취 허용량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Crohn's Disease
L-Glutamine 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.